ICCC vs IDXX · rev $17.5M vs P/E 40, rev $2.36B
ImmuCell Corporation (ICCC) versus IDEXX Laboratories Inc (IDXX) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
Latest reported ICCC revenue for 2026-06-30 was $17.5M. Net income was $3.8M. Revenue was up 69.4% from 2026-03-31 to 2026-06-30. ICCC currently screens at market cap $58.9M.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
ICCC currently screens at market cap $58.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Not investment advice. Open the ICCC and IDXX stock pages for the full models.
Not investment advice.